JP2016507470A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507470A5
JP2016507470A5 JP2015540879A JP2015540879A JP2016507470A5 JP 2016507470 A5 JP2016507470 A5 JP 2016507470A5 JP 2015540879 A JP2015540879 A JP 2015540879A JP 2015540879 A JP2015540879 A JP 2015540879A JP 2016507470 A5 JP2016507470 A5 JP 2016507470A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
antigen
seq
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015540879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507470A (ja
JP6694269B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/068624 external-priority patent/WO2014074540A2/en
Publication of JP2016507470A publication Critical patent/JP2016507470A/ja
Publication of JP2016507470A5 publication Critical patent/JP2016507470A5/ja
Application granted granted Critical
Publication of JP6694269B2 publication Critical patent/JP6694269B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015540879A 2012-11-06 2013-11-06 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体 Active JP6694269B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261723137P 2012-11-06 2012-11-06
US61/723,137 2012-11-06
US201361782405P 2013-03-14 2013-03-14
US61/782,405 2013-03-14
PCT/US2013/068624 WO2014074540A2 (en) 2012-11-06 2013-11-06 Antibodies to s. aureus surface determinants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019011283A Division JP2019089801A (ja) 2012-11-06 2019-01-25 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体

Publications (3)

Publication Number Publication Date
JP2016507470A JP2016507470A (ja) 2016-03-10
JP2016507470A5 true JP2016507470A5 (enExample) 2016-12-22
JP6694269B2 JP6694269B2 (ja) 2020-05-13

Family

ID=50685304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015540879A Active JP6694269B2 (ja) 2012-11-06 2013-11-06 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体
JP2019011283A Withdrawn JP2019089801A (ja) 2012-11-06 2019-01-25 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019011283A Withdrawn JP2019089801A (ja) 2012-11-06 2019-01-25 Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体

Country Status (16)

Country Link
US (3) US9879070B2 (enExample)
EP (2) EP2917360B1 (enExample)
JP (2) JP6694269B2 (enExample)
KR (1) KR102288394B1 (enExample)
CN (2) CN104968797B (enExample)
AU (2) AU2013341361A1 (enExample)
BR (1) BR112015010125A2 (enExample)
CA (1) CA2890427C (enExample)
DK (1) DK2917360T3 (enExample)
ES (1) ES2776179T3 (enExample)
HU (1) HUE049012T2 (enExample)
MX (2) MX375324B (enExample)
PL (1) PL2917360T3 (enExample)
RU (1) RU2698131C2 (enExample)
SG (2) SG11201503232TA (enExample)
WO (1) WO2014074540A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58190B2 (sr) 2011-02-08 2021-08-31 Medimmune Llc Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene
AU2012267732A1 (en) 2011-06-10 2014-01-09 Medimmune Limited Anti-Pseudomonas Psl binding molecules and uses thereof
WO2013070615A1 (en) * 2011-11-07 2013-05-16 Medlmmune, Llc. Combination therapies using anti- pseudomonas psl and pcrv binding molecules
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
EP2917360B1 (en) 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
ES2912267T3 (es) 2012-11-06 2022-05-25 Medimmune Llc Métodos de tratamiento de enfermedades asociadas a S. aureus
MX394895B (es) * 2014-06-03 2025-03-24 Xbiotech Inc Composiciones útiles para el tratamiento de infecciones por staphylococcus aureus.
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2016023943A1 (en) * 2014-08-12 2016-02-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
FR3033333A1 (fr) * 2015-03-06 2016-09-09 Commissariat Energie Atomique Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations
AU2016249837A1 (en) * 2015-04-17 2017-09-28 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
US20190077851A1 (en) * 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
CN105424930A (zh) * 2015-11-23 2016-03-23 天津科技大学 一种快速检测金黄色葡萄球菌的方法
BR112020004977A2 (pt) * 2017-09-29 2020-10-06 Regeneron Pharmaceuticals, Inc. moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos
MX2021000889A (es) 2018-07-24 2021-04-28 Medimmune Llc Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
MX2021004173A (es) 2018-10-09 2021-09-08 Medimmune Llc Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
WO2020076790A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
JP2022519631A (ja) 2019-02-12 2022-03-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法
JP7682795B2 (ja) 2019-03-13 2025-05-26 メディミューン，エルエルシー コロニー形成患者における黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）感染症の低減
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用
KR102397684B1 (ko) * 2019-12-09 2022-05-13 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩티드 및 이를 이용한 분석 방법
KR102504175B1 (ko) * 2020-06-17 2023-02-28 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩타이드, 이를 이용한 약물 복합체, 바이오센서 및 분석 방법
KR102674109B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드, 이를 포함하는 면역분석 장치 및 이를 이용한 면역분석 방법
KR102674098B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 멀티플렉스 면역분석 방법
KR102674120B1 (ko) * 2021-01-18 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 면역분석 방법

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017198A (en) * 1931-10-17 1935-10-15 Anglada Motor Corp Cuff valve engine
US20030044772A1 (en) 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002072600A2 (en) * 2001-01-26 2002-09-19 Inhibitex, Inc. Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
WO2005048917A2 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
CA2535171A1 (en) 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
US20100040606A1 (en) * 2006-03-06 2010-02-18 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009539979A (ja) * 2006-06-12 2009-11-19 ナビ バイオファーマシューティカルズ ブドウ球菌感染症を治療および予防するための、α毒素の使用
CA2667788A1 (en) * 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US9526774B1 (en) * 2006-11-06 2016-12-27 Microvax, Llc Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus
CA2713241C (en) * 2008-01-31 2022-10-04 Timothy Foster Treatment of microbial infections
WO2009140236A2 (en) * 2008-05-12 2009-11-19 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
WO2010005513A2 (en) * 2008-06-30 2010-01-14 The Texas A&M University System Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
US20110262477A1 (en) * 2008-10-06 2011-10-27 University Of Chicago Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins
US20120128673A1 (en) * 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
AU2010264538B2 (en) * 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
CN102666583B (zh) * 2009-07-15 2015-11-25 Aimm医疗股份公司 革兰氏阳性细菌特异性结合化合物
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
EP2516467A2 (en) * 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
EP2555794A4 (en) * 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
JP5793194B2 (ja) * 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
US20120202047A1 (en) 2011-02-07 2012-08-09 Baker Hughes Incorporated Nano-coatings for articles
RS58190B2 (sr) * 2011-02-08 2021-08-31 Medimmune Llc Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene
US9556281B2 (en) * 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
US9527927B2 (en) * 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
WO2013162746A1 (en) * 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
ES2912267T3 (es) * 2012-11-06 2022-05-25 Medimmune Llc Métodos de tratamiento de enfermedades asociadas a S. aureus
EP2917360B1 (en) * 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
CN104994875B (zh) * 2013-02-15 2018-10-09 免疫医疗公司 嵌合和人源化抗组蛋白抗体
US20160235832A1 (en) * 2013-10-15 2016-08-18 The Texas A&M University System Compositions and the Use of Fibrinogen Binding Motif Presence in EFB and COA for Vaccine Against Staphylococcus Aureus and Drug Delivery
WO2015106226A2 (en) * 2014-01-10 2015-07-16 University Of Rochester Diagnostic device and method for detection of staphylococcus infection
AU2015209140B2 (en) * 2014-01-24 2020-01-02 William R. Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
MX394895B (es) * 2014-06-03 2025-03-24 Xbiotech Inc Composiciones útiles para el tratamiento de infecciones por staphylococcus aureus.
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
AU2016249837A1 (en) 2015-04-17 2017-09-28 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
US20190077851A1 (en) * 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
WO2018009604A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
MX2021000889A (es) * 2018-07-24 2021-04-28 Medimmune Llc Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
WO2020076790A1 (en) * 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
MX2021004173A (es) * 2018-10-09 2021-09-08 Medimmune Llc Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
JP7682795B2 (ja) * 2019-03-13 2025-05-26 メディミューン，エルエルシー コロニー形成患者における黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）感染症の低減

Similar Documents

Publication Publication Date Title
RU2015121624A (ru) Антитела к поверхностным детерминантам s. aureus
JP2012010714A5 (enExample)
JP2021063090A5 (enExample)
JP2015514110A5 (enExample)
JP2019536806A5 (enExample)
JP2014205674A5 (enExample)
JP2014519334A5 (enExample)
JP2020500538A5 (enExample)
JP2015503909A5 (enExample)
JP2018535650A5 (enExample)
JP2017507652A5 (enExample)
JP2016513682A5 (enExample)
JP2017514461A5 (enExample)
JP2012504634A5 (enExample)
JP2017052784A5 (enExample)
JP2017528476A5 (enExample)
JP2010516229A5 (enExample)
JP2016536361A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2011514150A5 (enExample)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2006522830A5 (enExample)
JP2014526898A5 (enExample)
JP2018512435A5 (enExample)
JP2010526028A5 (enExample)